Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Postepy Hig Med Dosw (Online) ; 71(0): 867-875, 2017 Oct 13.
Artigo em Inglês | MEDLINE | ID: mdl-29039348

RESUMO

Toll-like receptors (TLR), especially TLR3, 7 and 9, play an important role in the pathogenesis of systemic lupus erythematosus (SLE). In our study blood was collected from 16 patients with SLE and from 8 healthy volunteers. Concentrations of IL-6, IL-10 and sIL-2R were measured by ELISA in mononuclear cell culture supernatant after 24 hours of stimulation by agonists and antagonists of TLR3 and 9 (for TLR3-poli I/C, resveratrol and for TLR9-ODN2006, IRS 945). Stimulation of TLR9 by ODN2006 led to an increase of IL-6 concentration in cell culture supernatants from the cells of healthy volunteers compared with unstimulated cells from controls. Inhibition of TLR3 activation by resveratrol caused a significantly lower concentration of IL-10 in cell culture supernatants derived from both patients and healthy donors. Moreover, resveratrol significantly decreased the level of IL-10 and sIL-2R in culture supernatants of cells derived from patients with active disease compared to the inactive stage. A positive correlation was also found between IL-6 concentration following ODN2006 administration and disease activity. In conclusions, our results indicate that TLRs play a role in the modulation of the inflammatory response in SLE patients. This suppressive action on IL-10 synthesis demonstrated by resveratrol suggests that it may be useful in SLE therapy.


Assuntos
Interleucina-10/metabolismo , Interleucina-6/metabolismo , Lúpus Eritematoso Sistêmico/metabolismo , Receptor 3 Toll-Like/fisiologia , Receptor Toll-Like 9/fisiologia , Adulto , Estudos de Casos e Controles , Pré-Escolar , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Imunossupressores/uso terapêutico , Leucócitos Mononucleares , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Masculino , Receptores de Interleucina-2/metabolismo , Receptor 3 Toll-Like/agonistas , Receptor 3 Toll-Like/antagonistas & inibidores , Receptor Toll-Like 9/agonistas , Receptor Toll-Like 9/antagonistas & inibidores
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA